D
rugs that inhibit platelet activation and aggregation reduce vascular events, notably myocardial infarction (MI) and ischemic stroke, and are generally associated with low rates of bleeding (1) . Available agents inhibit platelets via distinct mechanisms ( Table 1 is a price to pay with dual antiplatelet therapy: the lower risk of ischemic events cannot be dissociated from an increased bleeding risk, and, ironically, the most lethal toxicity of dual antiplatelet therapy for prevention of ischemic stroke is an increase in hemorrhagic stroke (4) (5) (6) .
In contrast to the advantage of dual antiplatelet therapy in patients with acute coronary syndromes, particularly those with potentially thrombogenic coronary stents, the net clinical benefit of combination antiplatelet therapy in patients with stable atherosclerotic vascular disease is less clear. In available trials, unexpected patient subgroups appear to benefit or not in complicated, sometimes confusing ways (7, 8) that was not pre-specified, the investigators' con- 
